Exicure, inc. announces support of ceo in its ongoing exploration of strategic alternatives

Chicago--(business wire)--exicure, inc. (nasdaq: xcur) (“exicure” or the “company”), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment of jung sang (michael) kim as chief executive officer and chief financial officer of t.
XCUR Ratings Summary
XCUR Quant Ranking